Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Goodwill (2024 - 2025)

Telix Pharmaceuticals has reported Goodwill over the past 2 years, most recently at $199.0 million for Q4 2025.

  • Quarterly Goodwill rose 198.84% to $199.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $199.0 million through Dec 2025, up 198.84% year-over-year, with the annual reading at $199.0 million for FY2025, 198.84% up from the prior year.
  • Goodwill was $199.0 million for Q4 2025 at Telix Pharmaceuticals, up from $66.6 million in the prior quarter.
  • Over five years, Goodwill peaked at $199.0 million in Q4 2025 and troughed at $66.6 million in Q4 2024.